U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07471867) titled 'Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention' on March 04.
Brief Summary: The purpose of this study is to evaluate the clinical utility of zastaprazan compared to proton pump inhibitors (PPIs) in patients receiving dual antiplatelet therapy (DAPT) including clopidogrel after percutaneous coronary intervention (PCI), by comparing their effects on platelet reactivity.
Study Start Date: March 17
Study Type: INTERVENTIONAL
Condition:
Chronic Coronary Syndrome
Intervention:
DRUG: Zastaprazan
Participants will receive Zastaprazan [20 mg] orally once daily for [6 month] in add...